https://www.live-feeds.com/feed/wegovy-maker-novo-faces-calls-to-map-out-strategy-beyond-weight-loss-drugsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/wegovy-maker-novo-faces-calls-to-map-out-strategy-beyond-weight-loss-drugshttps://www.live-feeds.com/feed/wegovy-maker-novo-faces-calls-to-map-out-strategy-beyond-weight-loss-drugs#u80532Tue, 22 Sep 2026 20:55:36 +0000Novo Nordisk shares have declined as investors express doubt over the company's growth strategy beyond its weight-loss drugs. To combat competition from Eli Lilly, the CEO stated the company aims to launch more than five blockbuster drugs by 2030. Novo plans to diversify its portfolio through bolt-on deals and new pipeline assets. However, the market remains unconvinced by these goals, with the CEO identifying pipeline concerns as the primary problem driving the current stock volatility.Why it mattersNovo Nordisk relies heavily on the success of Wegovy and Ozempic. The company is now atte